What regulatory or clinical trial risks were highlighted in the business update that could affect future timelines?

Regulatory and clinical‑trial risks mentioned in the update

The press release you provided summarizes Skye Bioscience’s Q2 2025 financial results and highlights “key accomplishments and upcoming milestones.” However, the excerpt you shared does not list any specific regulatory or clinical‑trial risks that could impact the company’s future timelines. All of the details in the summary focus on the company’s therapeutic focus (GPCR‑modulating molecules for obesity/overweight) and the fact that it reported its financial results and business update.

Because the text you supplied does not contain explicit statements about:

• potential delays in FDA or other health‑authority submissions,
• uncertainties around trial enrollment, patient‑population selection, or site‑activation,
• safety‑data read‑outs that might trigger a pause or redesign of a study,
• or any other regulatory or clinical‑development contingencies,

we cannot point to any particular risk factors that Skype Bioscience highlighted in this specific business update.

How to interpret the lack of risk disclosure

In earnings releases, companies often include a “Risk Factors” or “Forward‑looking Statements” section that outlines regulatory and clinical‑trial uncertainties (e.g., timing of IND filings, trial enrollment challenges, potential safety findings, or dependence on regulatory approvals). Since those sections are not present in the excerpt you provided, the only conclusion we can draw is that the release as shared does not call out any regulatory or clinical‑trial risks that might affect future timelines.

If you need a detailed list of the risks the company actually identified, you would need to review the full press release (or the accompanying 10‑Q filing) where Skye Bioscience typically includes a “Risk Factors” discussion. Those documents would contain the specific regulatory and clinical‑trial uncertainties the company believes could influence the timing of its programs.